CN112535292B - 一种唾液酸油悬液及其制备方法和应用 - Google Patents
一种唾液酸油悬液及其制备方法和应用 Download PDFInfo
- Publication number
- CN112535292B CN112535292B CN202011379797.2A CN202011379797A CN112535292B CN 112535292 B CN112535292 B CN 112535292B CN 202011379797 A CN202011379797 A CN 202011379797A CN 112535292 B CN112535292 B CN 112535292B
- Authority
- CN
- China
- Prior art keywords
- sialic acid
- oil suspension
- oil
- salt
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 165
- 239000012053 oil suspension Substances 0.000 title claims abstract description 106
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 23
- 150000003904 phospholipids Chemical group 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 abstract description 8
- 238000011068 loading method Methods 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 66
- 239000003921 oil Substances 0.000 description 43
- 238000010008 shearing Methods 0.000 description 41
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 34
- 229940090949 docosahexaenoic acid Drugs 0.000 description 33
- 239000004519 grease Substances 0.000 description 23
- 238000000227 grinding Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 239000000843 powder Substances 0.000 description 20
- 235000006708 antioxidants Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012525 sialic acid detection Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Edible Oils And Fats (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明实施例提供一种唾液酸油悬液及其制备方法和应用,所述唾液酸油悬液,为由唾液酸盐分散至含有多不饱和脂肪酸的油脂中形成的均一不分层的油悬液。本发明实施例提供的唾液酸油悬液以唾液酸盐分散在含有多不饱和脂肪酸的油脂中,可以在不添加稳定剂的情况下就形成均一不分层的油悬液,稳定性良好,而且可以大幅度提高唾液酸的载量,弥补了现有市场唾液酸相关产品的不足。
Description
技术领域
本发明涉及药品保健品领域,尤其涉及一种唾液酸油悬液及其制备方法和应用。
背景技术
唾液酸(SA)又称N-乙酰神经氨酸,广泛存在于动物组织及微生物中,通常位于细胞膜最外层的糖类部分和分泌的糖复合物(糖脂、糖蛋白和脂多糖)的关键位置,是糖复合物结构和功能多样化的重要物质基础。唾液酸具有提高婴儿智力和记忆力、抗老年痴呆、抗识别、抗病毒和提高肠道对维生素及矿物质的吸收等生理作用。随着人们对唾液酸生物学活性和应用的进一步研究和了解,由唾液酸生产的产品应运而生,对唾液酸的需求也随之增加。
多不饱和脂肪酸(PUFA)是指含有两个或两个以上双键且碳链长为18~22个碳原子的直链脂肪酸,是研究和开发功能性脂肪酸的主体和核心,主要包括亚油酸(LA)、γ-亚麻酸(GLA)、花生四烯酸(AA)、二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)等。多不饱和脂肪酸是所有细胞膜的重要成分,对机体的激素代谢和许多酶的活性起调控作用。
唾液酸和多不饱和脂肪酸对于健康的颇多益处,促使研究人员想将二者结合,共同发挥保健作用。但是,两者状态差异较大,唾液酸呈晶体颗粒状态,多不饱和脂肪酸存在于油脂中。如果只是普通的将SA分散于油脂中,由于SA的密度比油脂大,静置后会出现大量沉淀。在此前的研究过程中,申请人通过减小颗粒粒径、添加稳定剂成分来维持体系的稳定性,获得了令人满意的效果。但是如此制得的产品唾液酸载量有限,而唾液酸推荐的每日补充量为50-200mg,DHA的推荐补充量为100-200mg,若要使两者补充量达到平衡,需要进一步提高唾液酸载量,才能更便于下游应用。
发明内容
针对现有技术存在的问题,本发明实施例提供一种唾液酸油悬液及其制备方法和应用,该唾液酸油悬液无需加入稳定剂就能在较高载量下保持稳定。
本发明实施例提供一种唾液酸油悬液,为由唾液酸盐分散至含有多不饱和脂肪酸的油脂中形成的均一不分层的油悬液。
为了提高唾液酸油悬液的稳定性,发明人之前都是从唾液酸粒径或稳定剂的选用等角度入手进行研究,后来在实验中意外地发现,在油脂中唾液酸盐的分散性比唾液酸本身好,将唾液酸盐分散至油脂中形成的油悬液均一不分层,上层与底层的唾液酸盐含量差异不超过4%,而且无需加入稳定剂。
本发明所述唾液酸盐为唾液酸的药学上可接受的盐,包括钠盐、钾盐等。
所述多不饱和脂肪酸为二十二碳六烯酸、二十碳五烯酸、二十二碳五烯酸、花生四烯酸、γ-亚麻酸、二高-γ-亚麻酸或十八碳四烯酸中的一种或多种。
所述油脂的特征是:以油的总脂肪酸含量的重量%表示的至少一种如上脂肪酸(或其酯)。
在一个实施方式中,所述油脂包含至少约30重量%、至少约35重量%、至少约40重量%、至少约45重量%或至少约50重量%的一种或多种具有至少4个双键的多不饱和脂肪酸。在另一个实施方式中,所述油脂包含约30重量%至约60重量%、约30重量%至约50重量%、约30重量%至约40重量%、约40重量%至约60重量%或者约40重量%至约50重量%的一种或多种具有至少4个双键的多不饱和脂肪酸。
根据本发明实施例提供的唾液酸油悬液,所述唾液酸盐占所述油悬液的质量百分比为10%~60%,优选为40%~60%。
现有技术将唾液酸分散至含有多不饱和脂肪酸的油脂中,即使添加稳定剂,唾液酸的含量也难以提高到40%,不利于补充唾液酸至推荐量。而本发明在保证油悬液稳定性的情况下,可以使唾液酸盐含量超过40%,甚至达到60%,解决了现有技术无法高载量且保持稳定的问题。
本发明实施例还提供上述唾液酸油悬液的制备方法,包括:将粒径不大于100微米的唾液酸盐加入含有多不饱和脂肪酸的油脂中,进行分散。
其中,分散的手段可以是常规的剪切、研磨或均质手段,剪切可选用剪切机或球磨机,均质可选用均质机、球磨机或胶体磨。通过上述方法可以得到均一不分层的唾液酸油悬液,该方法简单可控,得到的油悬液中唾液酸盐的粒径不超过30微米。
根据本发明实施例提供的唾液酸油悬液的制备方法,还包括向所述含有多不饱和脂肪酸的油脂中加入抗氧化剂。
原本只是出于防止多不饱和脂肪酸氧化而考虑加入抗氧化剂,但是发明人实验中意外地发现抗氧化剂的加入能一定程度上增加体系的稳定性。所述抗氧化剂可以事先加到含有多不饱和脂肪酸的油脂中,也可以在制备油悬液的过程中加入含有多不饱和脂肪酸的油脂中,添加后所述抗氧化剂占所述油悬液的质量百分含量为0.01-2%。
所述抗氧化剂为磷脂、维生素E、抗坏血酸棕榈酸酯、二丁基羟基甲苯、丁基羟基茴香醚、迷迭香提取物中的一种或多种。
优选地,所述抗氧化剂为磷脂,所述油悬液中磷脂的质量百分含量为0.1%~2%。
根据本发明实施例提供的唾液酸油悬液的制备方法,当所述唾液酸油悬液中唾液酸盐的质量百分含量为40~60%时,所述制备方法还包括:将分散后获得的油悬液降温至8℃以下。
优选地,降温至-10~8℃,保持10-72h。
本发明旨在利用油脂中各脂肪酸的凝固点不同,使部分甘油三酯逐渐析出匀化后形成稳定的状态。经过降温处理后的油悬液在常温的放置下SA也能够不沉淀、油悬液也不会分层。
根据本发明实施例提供的唾液酸油悬液的制备方法,降温过程采用分段降温,每段降温2~15℃,并保持60-200min。实验发现分段降温对稳定性效果更好一些。
根据本发明实施例提供的唾液酸油悬液的制备方法,所述唾液酸盐的制备包括:先配制唾液酸水溶液,利用碱性食品添加剂调节溶液的pH至6~8,再进行干燥。
在本发明的优选实施方式中,所述唾液酸油悬液的制备具体如下:
(1)将SA溶于水中,在高速剪切下,按摩尔质量比添加碳酸氢钠等碱性食品添加剂,充分反应后,再选择性的加入填充剂(比如:麦芽糊精、固体玉米糖浆等)形成SA盐溶液;此时SA盐溶液的pH在6-8之间;
(2)将SA溶液直接经过喷雾干燥,得到SA盐粉,喷雾干燥条件如下:进风温度180-220℃,物料温度70-85℃,出风温度40-60℃,进料速度0-100L/h;
(3)将喷雾干燥得到的SA盐粉进行粉碎至粒径不大于100微米,可以用一般的粉碎机或球磨机,也可选用超微粉碎机;
(4)开启剪切机剪切含有多不饱和脂肪酸的油脂,再将SA盐细粉边剪切边加入到含有多不饱和脂肪酸的油脂中,接着加入0.1%-0.5%的磷脂进行剪切,剪切结束后将混合油溶液经过均质机均质3遍(二级压力0-10bar,一级压力1000-1500bar)或用球磨机研磨1-2h,研磨机转速达到最大转速的80%,得到SA油悬液。此时SA油悬液中唾液酸盐的粒径小于等于30微米,唾液酸盐占SA油悬液的质量百分比不超过60%;
(5)将步骤(4)获得的油悬液分段降温至-10~8℃,每段降温2~15℃并保持60-200min。
本发明实施例还提供上述唾液酸油悬液在制备保健品、食品或药品中的应用。
本发明还提供一种软胶囊,其内容物为上述唾液酸油悬液。由于唾液酸油悬液中使用的是唾液酸盐,pH为中性,因此制成的软胶囊胶皮不会变硬。
本发明实施例提供的唾液酸油悬液以唾液酸盐分散在含有多不饱和脂肪酸的油脂中,可以在不添加稳定剂的情况下就形成均一不分层的油悬液,颗粒状态稳定、油悬液整体稳定性良好,而且可以大幅度提高唾液酸的载量,弥补了现有市场唾液酸相关产品的不足。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下实施例中所用材料若无特别声明,均可以市售购得。
实施例1
本实施例提供SA盐,其中所使用的唾液酸为申请人自己生产用于市售的唾液酸,具体制备方法如下:
1、将SA溶于水中,在高速剪切下,按摩尔质量比添加碳酸氢钠食品添加剂,充分反应后,形成SA盐溶液,此时SA盐溶液的pH在6-8之间。
2、将SA盐溶液直接经过喷雾干燥,得到SA盐粉;喷雾干燥条件如下:进风温度220℃,物料温度80℃,出风温度40℃,进料速度100L/h。
3、将喷雾干燥得到的SA盐粉进行粉碎,使得唾液酸粒度不大于100微米。
按照上述方法制备三组SA盐,其中:
1组,pH调节到6;
2组,pH调节到7;
3组,pH调节到8。
实施例2
本实施例提供SA油悬液,其中使用的多不饱和脂肪酸油脂为申请人自己生产用于市售的DHA油脂,其中DHA的含量为45%。
实验1组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为20%(质量含量,下同),制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实验2组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为20%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实验3组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实验4组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实验组5组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,同时加入维生素E,维生素E的含量为0.5%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实验6组
(1)采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为,以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
(2)冬化,将油悬液降温至-4℃,保持12h,搅拌转速50HZ。
实验7组
(1)采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为,以20000rpm/min剪切DHA油脂,同时加入磷脂,磷脂的含量为0.1%再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力600bar),得到SA油悬液。
(2)冬化,将油悬液降温至8℃,保持12h,搅拌转速50HZ。
实验8组
(1)采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为,以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
(2)冬化,将油悬液分段降温,具体降温程序如表1所示。
表1实验6组中降温程序
程序编号 | 起始温度(℃) | 时间(min) | 搅拌转速(HZ) |
起始温度 | 28 | - | - |
1 | 15 | 240 | 20 |
2 | 0 | 240 | 30 |
3 | -4 | 240 | 30 |
实验9组
(1)采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为,以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
(2)冬化,将油悬液分段降温,具体降温程序如表2所示。
表2实验7组中降温程序
实验10组
(1)采用SA盐2组,油悬液中SA盐的含量为40%,制备工艺为,将SA盐细粉边研磨边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.1%,球磨机研磨1-2h,球磨机转速达到最大转速的80%,研磨30min。剪切结束后将混合油溶液经过球磨机研磨4h,得到SA油悬液。
(2)冬化,将油悬液分段降温,具体步骤如实验7组。
实验11组
(1)采用SA盐2组,油悬液中SA盐的含量为60%,制备工艺为,将SA盐细粉边研磨边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,球磨机研磨1-2h,球磨机转速达到最大转速的80%,研磨30min。剪切结束后将混合油溶液经过球磨机研磨4h,得到SA油悬液。
(2)冬化,将油悬液分段降温,具体步骤如实验7组。
实验12组(无冬化)
采用SA盐2组,油悬液中SA盐的含量为60%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA盐细粉边剪切边加入到DHA油脂中,同时加入磷脂,磷脂的含量为2%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
实施例13组(一步冬化)
(1)采用SA盐2组,油悬液中SA盐的含量为60%,制备工艺为,将SA盐细粉边研磨边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,球磨机研磨1-2h,球磨机转速达到最大转速的80%,研磨30min。剪切结束后将混合油溶液经过球磨机研磨4h,得到SA油悬液。
(2)冬化,将油悬液降温至-4℃,保持12h,搅拌转速50HZ。
实验14组
(1)采用SA盐1组,油悬液中SA盐的含量为40%,制备工艺为,将SA盐细粉边研磨边加入到DHA油脂中,同时加入磷脂,磷脂的含量为2%,球磨机研磨1-2h,球磨机转速达到最大转速的80%,研磨30min。剪切结束后将混合油溶液经过球磨机研磨4h,得到SA油悬液。
(2)冬化,将油悬液分段降温,具体步骤如实验7组。
实验15组
(1)采用SA盐3组,油悬液中SA盐的含量为40%,制备工艺为,将SA盐细粉边研磨边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,球磨机研磨1-2h,球磨机转速达到最大转速的80%,研磨30min。剪切结束后将混合油溶液经过球磨机研磨4h,得到SA油悬液。
(2)冬化,将油悬液分段降温,具体步骤如实验7组。
对比组1
采用SA晶体,油悬液中SA的含量为40%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA晶体边剪切边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
对比组2
采用SA晶体,油悬液中SA的含量为60%,制备工艺为:以10000rpm/min剪切DHA油脂,再将SA晶体边剪切边加入到DHA油脂中,同时加入磷脂,磷脂的含量为0.5%,剪切30min。剪切结束后将混合油溶液经过均质机均质3遍(二级压力8bar,一级压力1000bar),得到SA油悬液。
分析试验
油悬液稳定性分析,指标观察分层,上下含量是否无差距。
将油悬液置于试样瓶中,装样高度为10cm,封口,在25℃室温、相对湿度60%±10%条件下30天后,观察整体状态及唾液酸检测含量差异。上层取样不超过上液面以下的0.5cm处,底层取样不高于瓶底0.5cm。计算上层与底层的含量差异,并取绝对值。
唾液酸的检测方法为高效液相色谱法(HPLC),具体测试条件如下:岛津Lc-15c;检测柱Bio-Rad AMINEX HPX 87H Organic Analysis Column(300×7.8mm);柱温60℃;流动相为6mmol硫酸,流速0.6mL/min;检测波长210nm。分析结果如表3所示。
表3各组所得油悬液的分析结果
由以上结果可知,与唾液酸晶体相比,唾液酸盐在相同条件下更容易得到粒径更小的颗粒,并且唾液酸盐用在SA油悬液中使体系更容易稳定。抗氧化剂磷脂的加入能够一定程度上起到稳定的作用。采用降温工艺的油脂整体能够达到非常稳定的状态。油悬液中无需其它的稳定剂即可达到令人满意的效果。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (9)
1.一种唾液酸油悬液,其特征在于,为由唾液酸盐分散至含有多不饱和脂肪酸的油脂中形成的均一不分层的油悬液,所述唾液酸盐占所述油悬液的质量百分比为10%~60%。
2.权利要求1所述的唾液酸油悬液的制备方法,其特征在于,包括:将粒径不大于100微米的唾液酸盐加入含有多不饱和脂肪酸的油脂中,进行分散。
3.根据权利要求2所述的唾液酸油悬液的制备方法,其特征在于,还包括向所述含有多不饱和脂肪酸的油脂中添加抗氧化剂,添加后所述油悬液中所述抗氧化剂的质量百分含量为0.01-2%。
4.根据权利要求3所述的唾液酸油悬液的制备方法,其特征在于,所述抗氧化剂为磷脂,所述油悬液中磷脂的质量百分含量为0.1%~2%。
5.根据权利要求2~4任一项所述的唾液酸油悬液的制备方法,其特征在于,所述唾液酸油悬液中唾液酸盐的质量百分含量为40~60%时,所述制备方法还包括:将分散后获得的油悬液降温至8℃以下。
6.根据权利要求5所述的唾液酸油悬液的制备方法,其特征在于,降温过程采用分段降温,每段降温2~15℃,并保持60-200min。
7.根据权利要求2所述的唾液酸油悬液的制备方法,其特征在于,所述唾液酸盐的制备包括:先配制唾液酸水溶液,利用碱性食品添加剂调节溶液的pH至6~8,再进行干燥。
8.权利要求1所述的唾液酸油悬液在制备保健品、食品或药品中的应用。
9.一种软胶囊,其特征在于,其内容物为权利要求1所述的唾液酸油悬液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011379797.2A CN112535292B (zh) | 2020-11-30 | 2020-11-30 | 一种唾液酸油悬液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011379797.2A CN112535292B (zh) | 2020-11-30 | 2020-11-30 | 一种唾液酸油悬液及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112535292A CN112535292A (zh) | 2021-03-23 |
CN112535292B true CN112535292B (zh) | 2022-09-13 |
Family
ID=75016657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011379797.2A Active CN112535292B (zh) | 2020-11-30 | 2020-11-30 | 一种唾液酸油悬液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112535292B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170073366A1 (en) * | 2015-09-14 | 2017-03-16 | Ultragenyx Pharmaceutical Inc. | Crystal forms of sialic acid or salt or solvate thereof |
CN109463761A (zh) * | 2018-10-15 | 2019-03-15 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa油悬液及其制备方法 |
CN109601980A (zh) * | 2018-11-15 | 2019-04-12 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa软胶囊及其制备方法 |
-
2020
- 2020-11-30 CN CN202011379797.2A patent/CN112535292B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170073366A1 (en) * | 2015-09-14 | 2017-03-16 | Ultragenyx Pharmaceutical Inc. | Crystal forms of sialic acid or salt or solvate thereof |
CN109463761A (zh) * | 2018-10-15 | 2019-03-15 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa油悬液及其制备方法 |
CN109601980A (zh) * | 2018-11-15 | 2019-04-12 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa软胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112535292A (zh) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8075910B2 (en) | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions | |
US8202541B2 (en) | Dietary supplement composition for blood lipid health | |
EP3091860B1 (en) | Nutritional composition having lipophilic compounds with improved solubility and bioavailability | |
TW201513797A (zh) | 含有富集脂質之餾分的營養組成物及其用途 | |
Shi et al. | Effect of enzymatic degraded polysaccharides from Enteromorpha prolifera on the physical and oxidative stability of fish oil-in-water emulsions | |
TW201444480A (zh) | 包含結構性脂肪球之營養組成物及其用途 | |
CN105456190A (zh) | 一种复合口服脂肪纳米乳及其制备方法 | |
CN112535292B (zh) | 一种唾液酸油悬液及其制备方法和应用 | |
US20210251894A1 (en) | Functional beverage compositions and methods of using and making same | |
Shahidi et al. | Beverages fortified with omega-3 fatty acids, dietary fiber, minerals, and vitamins | |
CN112493477B (zh) | 唾液酸盐油悬液在制备胶囊中的应用 | |
CN110547457A (zh) | 一种多不饱和脂肪酸微胶囊及其制备方法和应用 | |
CN114158732A (zh) | 多不饱和脂肪酸甘三酯微胶囊粉末及其制备方法 | |
US10856564B2 (en) | Process for the preparation and stabilization of emulsions with Omega-3 by means of isometric crystalline networks of cellulose derivatives | |
EP2052727A2 (en) | Hoodia extract oil compositions comprising unsaturated monoacylglycerides | |
JP7398214B2 (ja) | サラシア属植物の抽出物を含有する経口組成物 | |
CN116036060A (zh) | 一种辅酶q10油剂及其制备方法和应用 | |
CN116746613A (zh) | 营养保健饮料 | |
CN112891304A (zh) | 一种高能量密度的脂肪乳剂及其制备方法和其应用 | |
CN103040914A (zh) | 杜仲籽油纳米乳注射液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |